亚洲免费av电影一区二区三区,日韩爱爱视频,51精品视频一区二区三区,91视频爱爱,日韩欧美在线播放视频,中文字幕少妇AV,亚洲电影中文字幕,久久久久亚洲av成人网址,久久综合视频网站,国产在线不卡免费播放

        ?

        Anti-oxidative stress treatment and current clinical trials

        2024-05-09 03:09:32ChunYeZhangMingYang
        World Journal of Hepatology 2024年2期

        Chun-Ye Zhang,Ming Yang

        Abstract Oxidative stress disturbs the balance between the production of reactive oxygen species (ROS) and the detoxification biological process.It plays an important role in the development and progression of many chronic diseases.Upon exposure to oxidative stress or the inducers of ROS,the cellular nucleus undergoes some biological processes via different signaling pathways,such as stress adaption through the forkhead box O signaling pathway,inflammatory response through the IκB kinase/nuclear factor-κB signaling pathway,hypoxic response via the hypoxia-inducible factor/prolyl hydroxylase domain proteins pathway,DNA repair or apoptosis through the p53 signaling pathway,and antioxidant response through the Kelch-like ECH-associated protein 1/nuclear factor E2-related factor 2 signaling pathway.These processes are involved in many diseases.Therefore,oxidative stress has gained more attraction as a targeting process for disease treatment.Meanwhile,anti-oxidative stress agents have been widely explored in pre-clinical trials.However,only limited clinical trials are performed to evaluate the efficacy of anti-oxidative stress agents or antioxidants in diseases.In this letter,we further discuss the current clinical trials related to anti-oxidative stress treatment in different diseases.More pre-clinical studies and clinical trials are expected to use anti-oxidative stress strategies as disease treatment or dietary supplementation to improve disease treatment outcomes.

        Key Words: Anti-oxidative stress treatment;Clinical trials;Drugs;Dietary invention;Reactive oxygen species

        TO THE EDITOR

        With great interest,we read a recently published review paper authored by Liet al[1],discussing the progress of using herbal extracts from traditional Chinese medicine as a therapeutic method to treat liver fibrosisviainhibiting oxidative stress.

        We agree with the authors that oxidative stress is a critical factor that can be targeted in the treatment of liver fibrosis.Oxidative stress is caused by an imbalance between the production and accumulation of reactive oxygen species (ROS)and the biological system to detoxify ROS products[2].The accumulation of ROS can cause cell damage through the destruction of proteins and lipids,genetic modification,and disturbance of cellular signaling[2,3].Therefore,oxidative stress has been recognized as a crucial factor involved in the underlying mechanisms of disease development and progression[4].In fact,oxidative stress has gained more and more attraction recently due to its important roles in many diseases,such as heart disease[5],cancer[6],hypertension[7],cardiovascular diseases[8],aging[9],neurodegenerative disease[10,11],Alzheimer's disease[12],Parkinson’s disease[13],and metabolic disorders.Moreover,oxidative stress also plays a pivotal role in organ transplantation[14] and infectious diseases[15].Therefore,anti-oxidative stress as a therapeutic strategy has gained more attention for disease treatment.

        Accumulating studies are performed to decipher the mechanism of oxidative stress in disease.Oxidative stress inducers include endogenous sources and exposomes[16].Endogenous sources can induce the endoplasmic reticulum stress that may be caused by misfolded proteins,resulting in elevated levels of ROS[17].The exposomes include but are not limited to toxins,irradiation exposure,air pollution,smoking,nutrients,chemicals,and infection[18].Upon exposure to oxidant sources,the cellular nucleus undergoes several biological processes (Figure 1),such as stress adaptionviathe forkhead box signaling pathway[19],inflammatory responses through the nuclear factor (NF)-κB and inhibitor of NF-κB kinase signaling pathway[20,21],hypoxic responses controlled by hypoxia-inducible facto-prolyl hydroxylase domain proteins[22],DNA repair or apoptosis process through the p53 signaling pathway[23],and antioxidant responses through the Kelch-like ECH-associated protein 1 (KEAP1)-transcription factor NF-E2 p45-related factor 2 (NRF2) (KEAP1-NRF2)signaling pathway[24].The mitochondrion serves as an important organelle to generate ATP as an energy source,and ROS is also produced in this process.The accumulated excessive levels of ROS can result in oxidative stress[25].Thus,the imbalance of the production of excessive oxidants and antioxidant processes leads to disease development and progression.

        Figure 1 Diagram illustrating reactive oxygen species including inducers,mechanisms,related diseases,and clinical trial treatments.Inducers include endogenous and exposomes.The mechanism includes the cell nucleus response to exposure to reactive oxygen species (ROS) and the mitochondrial ROS response.The imbalance between the accumulation of ROS and their clearance by the biological system results in ROS-related diseases such as heart disease,cancer,hypertension,cardiovascular diseases,Alzheimer’s disease,aging,neurodegenerative disease Parkinson’s disease,and metabolic disorder.Current clinical trials mainly focus on the drug and dietary invention.ER stress: Endoplasmic reticulum stress;ROS: Reactive oxygen species;IKK-NF-κB: IκB kinasenuclear factor-κB;HIF-PDHs: Hypoxia-inducible factor-prolyl hydroxylase domain proteins;p53: Tumor protein p53 or transformation-related protein 53;KEAP1-NRF2: Kelch-like ECH-associated protein 1-nuclear factor E2-related factor 2.All cartoons in this figure were prepared using Biorender (https://biorender.com,accessed on 7 January 2024).

        Inspired by this published review article,here,we give a further discussion on the current clinical trials that are related to anti-oxidative stress in different diseases using various intervention methods.Currently,two major categories including dietary supplement and drug treatment are used in clinical trials and summarized in this letter (Table 1).The most tested drug in these clinical trials is N-acetylcysteine with application in different diseases,such as cancer(melanoma and leukemia),pulmonary disease,renal disease,liver diseases such as non-alcoholic fatty liver disease,infectious diseases including severe acute respiratory syndrome coronavirus and human immunodeficiency virus infections,obesity,Parkinson's disease,and depressive disorders.The drug melatonin has also been used in many diseases,such as necrotizing enterocolitis,multiple sclerosis,and septic shock.Curcumin is a dietary supplement,which has been tested for renal transplantation disorder,coronary artery disease,metabolic syndrome,kidney disease,and others (Table 1).The data were collected from the website https://clinicaltrials.gov (accessed on October 28,2023) using the keywords anti-oxidative stress,disease,and treatments such as drugs and nutrients,including ongoing and completed clinical trials.

        Table 1 Clinical trials on anti-oxidative stress-related treatment

        In summary,oxidative stress is involved in many diseases and functions as a promising target in disease treatment and therapeutic drug screening.More potent antioxidants are expected to be explored to improve treatment outcomes.Meanwhile,the synergistic application of anti-oxidative drugs is an option to improve the therapeutic efficacy of other drugs.

        FOOTNOTES

        Author contributions:Zhang CY and Yang M designed the study,collected the data,and wrote,revised,and finalized the manuscript.

        Conflict-of-interest statement:All the authors report no relevant conflicts of interest for this article.

        Open-Access:This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers.It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license,which permits others to distribute,remix,adapt,build upon this work non-commercially,and license their derivative works on different terms,provided the original work is properly cited and the use is non-commercial.See: https://creativecommons.org/Licenses/by-nc/4.0/

        Country/Territory of origin:United States

        ORCID number:Chun-Ye Zhang 0000-0003-2567-029X;Ming Yang 0000-0002-4895-5864.

        S-Editor:Qu XL

        L-Editor:Wang TQ

        P-Editor:Zheng XM

        日本亚洲国产一区二区三区| 精品国产一区二区三区三| 久久无码人妻一区二区三区午夜| 男受被做哭激烈娇喘gv视频| 国产AⅤ无码久久丝袜美腿| 亚洲伊人久久综合精品| 国产丝袜爆操在线观看| 国产七十六+老熟妇| 免费现黄频在线观看国产| 无码伊人久久大香线蕉| av在线播放亚洲天堂| 丰满少妇人妻无码专区| 日本55丰满熟妇厨房伦| 国产亚洲AV片a区二区| 国产三级精品三级在线专区 | 国产亚洲中文字幕久久网| 国产欧美日韩va另类在线播放| 牲欲强的熟妇农村老妇女| 久久免费精品国产72精品剧情| 视频在线亚洲视频在线| 乱色欧美激惰| 曰本女人牲交全视频免费播放| 麻豆国产成人AV网| 日韩精品一二三区乱码| 天天爽夜夜爱| 91av视频在线| 日韩精品一区二区三区视频 | 亚洲肥老熟妇四十五十路在线| 亚洲国产av一区二区三| 国产乱理伦在线观看美腿丝袜| 久久精品噜噜噜成人| 成人午夜免费无码视频在线观看| 亚洲国产天堂av成人在线播放 | 中文字幕无码精品亚洲资源网久久| 国产精品国产三级国产an| av中国av一区二区三区av| 无码乱人伦一区二区亚洲一 | 色 综合 欧美 亚洲 国产| 欧美一区二区午夜福利在线yw| 精品人妻午夜中文字幕av四季| 国产亚洲精品第一综合另类|